OOIR: Observatory of International Research

Papers

(The TQCC of Clinical & Translational Immunology is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Endothelial cells are not productively infected by SARS‐CoV‐2	88
Antibodies against type I interferon: detection and association with severe clinical outcome in COVID‐19 patients	75
CAR‐NK cells: the next wave of cellular therapy for cancer	68
A scalable serology solution for profiling humoral immune responses to SARS‐CoV‐2 infection and vaccination	65
Comprehensive analysis of SARS‐CoV‐2 antibody dynamics in New Zealand	47
Preclinical development of a molecular clamp‐stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2	45
Dynamics of antibodies to SARS‐CoV‐2 in convalescent plasma donors	44
Allogeneic CD20‐targeted γδ T cells exhibit innate and adaptive antitumor activities in preclinical B‐cell lymphoma models	44
Pattern of circulating SARS‐CoV‐2‐specific antibody‐secreting and memory B‐cell generation in patients with acute COVID‐19	41
Patient‐derived organoids of bladder cancer recapitulate antigen expression profiles and serve as a personal evaluation model for CAR‐T cells in vitro	41
Rheumatoid arthritis CD14⁺ monocytes display metabolic and inflammatory dysfunction, a phenotype that precedes clinical manifestation of disease	38
Arrested development: suppression of NK cell function in the tumor microenvironment	36
Kinetics of peripheral blood neutrophils in severe coronavirus disease 2019	34
SARS‐CoV‐2‐specific humoral and cellular immunity persists through 9 months irrespective of COVID‐19 severity at hospitalisation	34
Pathogenesis of autoimmune demyelination: from multiple sclerosis to neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody‐associated disease	34
Decline in neutralising antibody responses, but sustained T‐cell immunity, in COVID‐19 patients at 7 months post‐infection	34
Type 1 conventional dendritic cells and interferons are required for spontaneous CD4⁺ and CD8⁺ T‐cell protective responses to breast cancer	34
RGD‐binding integrins and TGF‐β in SARS‐CoV‐2 infections – novel targets to treat COVID‐19 patients?	32
The up‐to‐date pathophysiology of Kawasaki disease	31
The complex interplay between endoplasmic reticulum stress and the NLRP3 inflammasome: a potential therapeutic target for inflammatory disorders	31
Natural killer cells in inflammatory autoimmune diseases	31
Cerebrospinal fluid metabolomics: detection of neuroinflammation in human central nervous system disease	30
Cardiovascular disease in SARS‐CoV‐2 infection	29
Robust correlations across six SARS‐CoV‐2 serology assays detecting distinct antibody features	26
Molecular and cellular mechanisms of itch and pain in atopic dermatitis and implications for novel therapeutics	26

Ligelizumab treatment for severe asthma: learnings from the clinical development programme	26
Prophylactic antigen‐specific T‐cells targeting seven viral and fungal pathogens after allogeneic haemopoietic stem cell transplant	26
Lysine methyltransferase G9a is an important modulator of trained immunity	25
Influenza, but not SARS‐CoV‐2, infection induces a rapid interferon response that wanes with age and diminished tissue‐resident memory CD8⁺ T cells	25
An acetate‐yielding diet imprints an immune and anti‐microbial programme against enteric infection	24
Systematic evaluation of SARS‐CoV‐2 antigens enables a highly specific and sensitive multiplex serological COVID‐19 assay	24
TGF‐β‐secreting regulatory B cells: unsung players in immune regulation	24
High levels of soluble CD25 in COVID‐19 severity suggest a divergence between anti‐viral and pro‐inflammatory T‐cell responses	23
Off‐target effects of bacillus Calmette–Guérin vaccination on immune responses to SARS‐CoV‐2: implications for protection against severe COVID‐19	22
Humoral immunity against SARS‐CoV‐2 variants including omicron in solid organ transplant recipients after three doses of a COVID‐19 mRNA vaccine	21
Circular RNA TRAPPC6B inhibits intracellular Mycobacterium tuberculosis growth while inducing autophagy in macrophages by targeting microRNA‐874‐3p	21
Blunted sFasL signalling exacerbates TNF‐driven neutrophil necroptosis in critically ill COVID‐19 patients	21
Impact of SARS‐CoV‐2 infection on vaccine‐induced immune responses over time	20
Improvement of Treg immune response after treatment with tocilizumab in giant cell arteritis	19
Memory stem T cells modified with a redesigned CD30‐chimeric antigen receptor show an enhanced antitumor effect in Hodgkin lymphoma	19
Heterogeneous magnitude of immunological memory to SARS‐CoV‐2 in recovered individuals	19
Autoantibodies against complement component C1q in systemic lupus erythematosus	19
Inflammatory marker trajectories associated with frailty and ageing in a 20‐year longitudinal study	19
Modelling the tumor immune microenvironment for precision immunotherapy	19
Circulating CD8⁺ mucosal‐associated invariant T cells correlate with improved treatment responses and overall survival in anti‐PD‐1‐treated melanoma patients	17
Characteristics of T‐cell responses in COVID‐19 patients with prolonged SARS‐CoV‐2 positivity – a cohort study	17
Optimising the IgG‐degrading enzyme treatment regimen for enhanced adeno‐associated virus transduction in the presence of neutralising antibodies	17
Increased GM‐CSF‐producing NCR^‐ ILC3s and neutrophils in the intestinal mucosa exacerbate inflammatory bowel disease	16
Human neutralising antibodies elicited by SARS‐CoV‐2 non‐D614G variants offer cross‐protection against the SARS‐CoV‐2 D614G variant	16
Landscape of T‐cell repertoires with public COVID‐19‐associated T‐cell receptors in pre‐pandemic risk cohorts	16
Differential transcriptional and functional properties of regulatory T cells in HIV‐infected individuals on antiretroviral therapy and long‐term non‐progressors	16
SLAMF8 expression predicts the efficacy of anti‐PD1 immunotherapy in gastrointestinal cancers	16
Nalfurafine reduces neuroinflammation and drives remyelination in models of CNS demyelinating disease	16
Tear antibodies to SARS‐CoV‐2: implications for transmission	15
Whole‐blood cytokine secretion assay as a high‐throughput alternative for assessing the cell‐mediated immunity profile after two doses of an adjuvanted SARS‐CoV‐2 recombinant protein vaccine candidate	15
IL‐17 drives salivary gland dysfunction via inhibiting TRPC1‐mediated calcium movement in Sjögren’s syndrome	15
T‐cell response after first dose of BNT162b2 SARS‐CoV‐2 vaccine among healthcare workers with previous infection or cross‐reactive immunity	15
SARS‐CoV‐2 triggers complement activation through interactions with heparan sulfate	15
Proinsulin‐specific T‐cell responses correlate with estimated c‐peptide and predict partial remission duration in type 1 diabetes	15
Sustained low‐dose interleukin‐2 therapy alleviates pathogenic humoral immunity via elevating the Tfr/Tfh ratio in lupus	15
Novel high‐affinity EGFRvIII‐specific chimeric antigen receptor T cells effectively eliminate human glioblastoma	15
C‐reactive protein flare‐response predicts long‐term efficacy to first‐line anti‐PD‐1‐based combination therapy in metastatic renal cell carcinoma	15
Tumor‐associated neutrophils (TANs) in human carcinoma‐draining lymph nodes: a novel TAN compartment	14
Quantification and role of innate lymphoid cell subsets in Chronic Obstructive Pulmonary Disease	14
Mutated GM‐CSF‐based CAR‐T cells targeting CD116/CD131 complexes exhibit enhanced anti‐tumor effects against acute myeloid leukaemia	14
Next‐generation Bruton's tyrosine kinase inhibitor BIIB091 selectively and potently inhibits B cell and Fc receptor signaling and downstream functions in B cells and myeloid cells	14
Inflammation neuroscience: neuro‐immune crosstalk and interfaces	14
Adaptive immunity to human coronaviruses is widespread but low in magnitude	13
Regulation of the human NK cell compartment by pathogens and vaccines	13
Adenoviral vector‐based platforms for developing effective vaccines to combat respiratory viral infections	13
Epigenetic programming underpins B‐cell dysfunction in peanut and multi‐food allergy	13
IgM and IgA augmented autoantibody signatures improve early‐stage detection of colorectal cancer prior to nodal and distant spread	13
Perivascular macrophages create an intravascular niche for CD8⁺ T cell localisation prior to the onset of fatal experimental cerebral malaria	13
Antibodies to neutralising epitopes synergistically block the interaction of the receptor‐binding domain of SARS‐CoV‐2 to ACE 2	13
Inflammasome activation: from molecular mechanisms to autoinflammation	12

Novel high‐affinity EGFRvIII‐specific chimeric antigen receptor T cells effectively eliminate human glioblastoma	12
Exploiting the CRISPR‐Cas9 gene‐editing system for human cancers and immunotherapy	12
Glycolipid‐peptide conjugate vaccines elicit CD8⁺ T‐cell responses and prevent breast cancer metastasis	12
Rapid whole‐blood assay to detect SARS‐CoV‐2‐specific memory T‐cell immunity following a single dose of AstraZeneca ChAdOx1‐S COVID‐19 vaccine	11
Intratumoral injection of caerin 1.1 and 1.9 peptides increases the efficacy of vaccinated TC‐1 tumor‐bearing mice with PD‐1 blockade by modulating macrophage heterogeneity and the activation of CD8	11
Human regulatory T cells locally differentiate and are functionally heterogeneous within the inflamed arthritic joint	11
Parallel detection of SARS‐CoV‐2 epitopes reveals dynamic immunodominance profiles of CD8⁺ T memory cells in convalescent COVID‐19 donors	11
Impact of adaptive natural killer cells, KLRC2 genotype and cytomegalovirus reactivation on late mortality in patients with severe COVID‐19 lung disease	11